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Summary
This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using 
patient-level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/
refractory multiple myeloma [MM]. Seven clinically relevant primary (congestive heart failure 
[CHF], arrhythmias, ischaemic heart disease [IHD], cardiac death) and secondary (hypertension, 
dyspnoea, oedema) cardiac endpoints were defined based on MedDRA v16.0 preferred terms. 
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2509 bortezomib-treated patients and 1445 patients in non-bortezomib-based control arms were 
included. The incidence of grade ≥3 CHF was 1·3–4·0% in studies in relapsed/refractory MM and 
1·2–4·7% in previously untreated MM (2·0–7·6% all grades), with no significant differences 
between bortezomib- and non-bortezomib-based arms in comparative studies. Incidences of 
arrhythmias (1·3–5·9% grade ≥2; 0·6–4·1% grade ≥3), IHD (1·2–2·9% all grades; 0·4–2·7% grade 
≥3) and cardiac death (0–1·4%) were low, with no differences between bortezomib-based and non-
bortezomib-based arms. Higher rates of oedema (mostly grade 1/2) were seen in bortezomib-based 
versus non-bortezomib-based arms in one study and a pooled transplant study analysis. Logistic 
regression analyses of comparative studies showed no impact on cardiac risk with bortezomib-
based versus non-bortezomib-based treatment. Bortezomib-based treatment was associated with 
low incidences of cardiac events.
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Introduction
Due to recent treatment advances, patients with multiple myeloma (MM) are living longer 
(Anderson, 2012; Kumar et al, 2014; Liwing et al, 2014), underscoring the importance of 
patient quality of life and management of adverse events (AEs) related to therapy. MM 
patients are at risk of cardiac events due to age and disease-related factors (Kistler et al, 
2012; McBride et al, 1988; Inanir et al, 1998; Robin et al, 2008; Kwaan, 2013); there is also 
a risk of cardiac events due to cardiotoxicity from treatments including anthracyclines (Ky et 
al, 2013), proteasome inhibitors (Bockorny et al, 2012; Herndon et al, 2013; Honton et al, 
2013; Lonial et al, 2012; Siegel et al, 2013) and high-dose therapy (Chow et al, 2011; 
Sureddi et al, 2012; Fatema et al, 2009).
The United States Food and Drug Administration (US FDA)-approved proteasome 
inhibitors, bortezomib, carfilzomib and ixazomib, have been associated with cardiac events 
in MM patients (Bockorny et al, 2012; Herndon et al, 2013; Honton et al, 2013; Lonial et al, 
2012; Siegel et al, 2013; Moreau et al, 2016). Cardiac toxicity and cardiac adverse reactions 
are included under ‘Warnings and Precautions’ in the respective US labels for bortezomib 
and carfilzomib (http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf). 
Case reports have described cardiac failure and other cardiotoxicity with bortezomib 
treatment in patients with MM and other cancers (Bockorny et al, 2012; Dasanu, 2011; 
Enrico et al, 2007; Hacihanefioglu et al, 2008; Lee et al, 2011; Takamatsu et al, 2010; 
Voortman & Giaccone, 2006; Gupta et al, 2012; Subedi et al, 2014). However, case reports 
do not provide a comprehensive picture of the cardiovascular risk profile of bortezomib. 
More than 550 000 patients worldwide have been treated with bortezomib; its development 
involved numerous large, randomised, controlled clinical trials in relapsed and/or refractory 
MM (RRMM) (Moreau et al, 2011; Orlowski et al, 2007; Richardson et al, 2005) and newly 
diagnosed MM (NDMM) (Cavo et al, 2010; Harousseau et al, 2010; Rosinol et al, 2012; San 
Miguel et al, 2008; Sonneveld et al, 2012). This large, accumulated experience offers the 
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opportunity to define a benchmark for describing the cardiovascular profile of proteasome 
inhibitors in MM.
We conducted a retrospective analysis of the risk of heart failure, arrhythmias, ischaemic 
heart disease (IHD), cardiac death, hypertension, dyspnoea and oedema associated with 
bortezomib, using patient-level data from MM studies that supported US and European 
Union (EU) regulatory approvals (Cavo et al, 2010; Harousseau et al, 2010; Richardson et 
al, 2003; Richardson et al, 2005; Rosinol et al, 2012; San Miguel et al, 2008; Sonneveld et 
al, 2012; Sonneveld et al, 2013; Moreau et al, 2011; Orlowski et al, 2007). The aim was to 
establish the overall cardiac safety profile of bortezomib, using a clearly defined, 
standardised and replicable reporting method. This approach aimed to reconcile 
discrepancies between the National Cancer Institute’s (NCI) Common Terminology Criteria 
for AEs (CTCAE) and the Medical Dictionary for Regulatory Activities (MedDRA) 
regarding AE reporting, and used Standardised MedDRA Queries (SMQ) as the basis for 
grouping preferred terms to specified cardiovascular entities.
Patients and methods
Studies analysed
This pooled analysis included data on male/female patients in all phase 3 MM studies that 
led to US/EU regulatory approval, plus the original phase 2 registration study for US/EU 
regulatory approval, and represented all such studies with patient-level data available (Table 
I). RRMM studies included: phase 2 Study of Uncontrolled Multiple Myeloma Managed 
with Proteasome Inhibition Therapy (SUMMIT) study of bortezomib with/without 
dexamethasone (M34100-025) (Richardson et al, 2003); phase 3 APEX (Assessment of 
Proteasome Inhibition for Extending Remissions) trial of single-agent bortezomib versus 
dexamethasone (NCT00048230) (Richardson et al, 2005); phase 3 MMY-3001 trial of 
bortezomib plus liposomal doxorubicin versus single-agent bortezomib (NCT00103506) 
(Orlowski et al, 2007); phase 3 MMY-3021 trial of subcutaneous (SC) versus intravenous 
(IV) bortezomib (with/without dexamethasone; NCT00722566) (Moreau et al, 2011). 
NDMM studies included the phase 3 VISTA (Velcade® as Initial Standard Therapy in 
Multiple Myeloma) trial of bortezomib-melphalan-prednisone (VMP) versus melphalan-
prednisone (MP) in elderly transplant-ineligible patients (NCT00111319) (San Miguel et al, 
2008), and a pooled analysis based on patient-level data from 3 phase 3 trials of bortezomib-
based versus non-bortezomib-based induction therapy in transplant-eligible patients (FM 
2005-01, NCT00200681; GEM2005MENOS65, NCT00461747; HOVON-65/GMMG-HD4: 
EudraCT 2004-000944-26) (Sonneveld et al, 2013). Unfortunately, it was not possible to 
obtain patient level data from the Gruppo Italiano Malattie Ematologiche dell’Adulto 
(GIMEMA) study (NCT01134484) (Cavo et al, 2010).
Analyses of cardiac AEs
Seven clinically relevant cardiac entities/disease states were selected for analysis (Table SI). 
The 4 primary endpoints for this analysis were heart failure (congestive heart failure [CHF]), 
arrhythmia(s), IHD and cardiac death. For arrhythmias, only AEs of grade 2 severity or 
greater were included (based on clinical relevance and to improve specificity); ventricular 
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arrhythmias were described as a distinct subgroup. Incidences of hypertension, dyspnoea 
and oedema were included as secondary endpoints; dyspnoea AEs occurring in conjunction 
with CHF were analysed as a distinct subgroup.
Patient-level data from study databases were analysed retrospectively for treatment-emergent 
AEs (AEs occurring up to 30 days after last dose of study drug [20 days in SUMMIT], or 
regardless of start date for drug-related events) within the 7 cardiac endpoints. Different 
studies used different terminology criteria for recording and grading AEs: NCI Common 
Toxicity Criteria version 2.0 and CTCAE version 3.0. Relevant AEs were analysed and re-
coded for consistency across studies. MedDRA SMQ version 16.0 was used for developing 
lists of preferred terms for inclusion in the primary and secondary cardiac endpoints, which 
were mapped to older versions of MedDRA. All terms were reviewed by 2 cardiologists and 
included, excluded or mapped to another cardiac endpoint on the basis of clinical relevance 
(Table SI), a methodology that has been previously employed (Basaria et al, 2010).
Statistical methods
For each endpoint, the primary descriptive analysis was incidence of events (patients with 
AE/total patients). Hazard of events over time was analysed using Kaplan–Meier 
methodology; each patient contributed 1 (first) event. Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were estimated using Cox proportional hazards models with 
statistical significance determined (α = 0.05 level) using the log-rank test. Logistic 
regression models were used for each comparative study to determine parameters 
independently affecting risk of each cardiac endpoint. Parameters included treatment 
assignment, age (≤70 vs. >70 years), cardiac history (yes/no, defined as ‘any abnormal 
finding in the cardiovascular system organ class’, and per individual study definitions of 
cardiac history, Table I), interaction of treatment assignment and age, interaction of 
treatment assignment and cardiac history, and interaction of age and cardiac history. Due to 
marked heterogeneity across patient populations (transplant eligible, transplant ineligible 
and RRMM) and treatments (single-agent bortezomib, various combination regimens), data 
were not combined across studies except for transplant induction studies, which were 
conducted in the same patient population.
Results
Patients
Data from 3954 patients (2509 bortezomib treated, 1445 non-bortezomib treated) were 
included (Table I). In comparative studies, cardiac risk factors (age, prior cardiac history) 
were balanced between bortezomib- and non-bortezomib-based arms. Median age ranged 
from 57 years in the pooled transplant induction analysis to 71 years in VISTA; rate of prior 
cardiac history, defined in Table I, ranged from 21% to 74%, respectively.
Cardiac events
Primary endpoints: The incidence of grade ≥3 CHF across bortezomib-based arms was 
1·3–4·0% in RRMM studies and 1·2–4·7% in NDMM (Table II); overall incidences were 
2·0–7·4% in RRMM and 3·1–7·6% in NDMM. There were no significant differences in the 
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hazard of CHF over time between bortezomib- and non-bortezomib-based arms in 
comparative studies (Fig 1). The incidence of all-grade CHF was higher with bortezomib 
plus liposomal doxorubicin versus bortezomib in MMY-3001 (HR 0·42, P = 0·017) due to 
the difference in grade 1/2 events (5·9% vs. 1·6%). However, there was minimal difference 
in the incidence of grade ≥3 CHF between bortezomib plus liposomal doxorubicin and 
bortezomib (1·3% vs. 1·6%) in the overall population of the MMY-3001 study.
The incidence of grade ≥3 arrhythmias across bortezomib-based arms was 0·6–1·8% in 
RRMM studies and 1·7–4·1% in NDMM (Table III); incidences of grade ≥2 events were 
1·3–4·1% in RRMM and 3·5–5·9% in NDMM. No significant differences between 
bortezomib- and non-bortezomib-based arms were seen. Most events were supraventricular 
arrhythmias; only 7 cases of ventricular arrhythmias were identified across all studies (5 in 
bortezomib-treated and 2 in non-bortezomib-treated patients; incidences of 0–0·5%; data not 
shown).
Grade ≥3 IHD was seen in 0·5–2·7% of bortezomib-treated patients in RRMM studies and 
0·4–1·5% in NDMM (Table IV); overall incidences in individual studies were 1·5–2·7% in 
RRMM and 1·2–2·9% in NDMM. No significant differences between bortezomib- and non-
bortezomib-based arms were seen.
Incidences of cardiac death were low; no meaningful statistical comparisons between 
treatment arms/groups were feasible. In RRMM, the incidence was 1·0% (n = 2) with 
bortezomib ± dexamethasone in SUMMIT, 0·6% (n = 2) versus 0 with bortezomib versus 
dexamethasone in APEX, 0·6% (n = 2) in both arms of MMY-3001, and 0·7% (n = 1) versus 
1·4% (n = 1) with SC versus (IV bortezomib in MMY-3021. In NDMM, incidences were 0 
versus 0·9% (n = 3) with VMP versus MP in VISTA, and 0·3% (n = 2) versus 0 with 
bortezomib-based versus non-bortezomib-based induction therapy in the pooled transplant 
analysis.
Secondary endpoints: Grade ≥3 hypertension was reported in 0–2·0% of bortezomib-
treated patients in RRMM and 1·5–2·9% in NDMM; overall incidences were 3·5–9·5% in 
RRMM and 5·1–13·5% in NDMM (Table V). Rates appeared numerically higher with 
bortezomib versus non-bortezomib treatment in comparative studies, with a trend towards 
increased rates of all-grade (HR 1·54, P = 0·0656) and grade ≥3 (HR 2·94, P = 0·0881) 
hypertension with VMP versus MP in VISTA.
Grade ≥3 dyspnoea (regardless of cause) was reported in 0·9–5·4% of bortezomib-treated 
patients in RRMM studies and 1·2–3·8% in NDMM, with overall incidences of 7·5–22·3% 
in RRMM and 6·4–15·3% in NDMM (Table SII). No significant differences were seen in 
rates of dyspnoea between bortezomib- and non-bortezomib-based arms in comparative 
studies (Fig 1). Incidences of dyspnoea occurring in conjunction with CHF were low with 
bortezomib-based treatment (0–3·9% overall; 0–1·2% grade ≥3; Table SIII), with a 
significantly greater rate of all-grade events with bortezomib versus dexamethasone in 
APEX (HR 6·10, P = 0·0066).
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Incidences of grade ≥3 oedema (regardless of cause) were low with bortezomib-based 
treatment (0–0·3% in RRMM; 0·6–1·2% in NDMM). Overall incidences were 3·0–11·9% in 
RRMM and 23·5% in NDMM (Table SIV), with significantly higher rates with VMP versus 
MP in VISTA (HR 2·24, P < 0·0001) and with bortezomib- versus non-bortezomib-based 
induction therapy in the pooled transplant analysis (HR 1·54, P = 0·0002).
Analysis of risk factors
In APEX, logistic regression model analysis showed no added risk of any cardiac endpoint 
with bortezomib compared with dexamethasone. In patients aged ≤70 years, independent of 
treatment, there was a significantly higher risk of dyspnoea occurring in conjunction with 
CHF in patients with versus without prior cardiac history. In patients randomised to 
dexamethasone, patients aged >70 years had a significantly higher risk of hypertension. 
Logistic regression model analysis identified no independent parameters that significantly 
affected the incidence of any cardiac endpoint in the MMY-3001, MMY3021 and VISTA 
studies. In the pooled transplant analysis, patients with prior cardiac history had a 
significantly higher risk of CHF, oedema and hypertension, independent of treatment.
Discussion
Bortezomib-based treatment was associated with generally low incidences of all-grade and 
grade ≥3 cardiac AEs across studies included in this analysis in NDMM and RRMM, 
supporting guidance in the current prescribing information that cardiac monitoring is most 
appropriate in those patients with risk factors for heart disease, or who have existing heart 
disease. No significant differences were seen in comparative studies of bortezomib- versus 
non-bortezomib-based treatment in CHF, arrhythmias, IHD and cardiac death (primary 
endpoints). The same was true for the secondary endpoints, except for a higher rate of all-
grade oedema with VMP in VISTA and with bortezomib-based induction in the pooled 
transplant analysis, a higher rate of all-grade dyspnoea in conjunction with CHF with 
bortezomib in APEX, and a trend towards higher rates of hypertension with VMP in VISTA. 
Additionally, there was a significantly higher rate of any-grade CHF with bortezomib plus 
liposomal doxorubicin versus bortezomib in MMY-3001, possibly associated with the 
cardiac safety profile of anthracyclines; this differs from the primary manuscript findings 
(Orlowski et al, 2007), probably due to the broader range of preferred terms incorporated in 
this analysis. Prior meta-analysis has shown that bortezomib combination treatment did not 
increase the cardiac toxicity compared with bortezomib monotherapy (Xiao et al, 2014). 
Furthermore, data from the MMY-3021 study of SC versus IV bortezomib did not show any 
consistent differences between arms in cardiac risk; however, patient and event numbers are 
very small.
Notably, the absence of differences in all primary and most secondary endpoints between 
bortezomib- and non-bortezomib-based treatment was not affected in logistic regression 
model analyses of risk factors. These findings indicate that relative cardiac risk is not 
modified by bortezomib treatment and suggest that proteasome inhibition therapy with 
bortezomib may be an appropriate option in patients with cardiac risk factors, such as older 
age and cardiac history (acknowledging the cardiac study eligibility criteria, discussed 
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below). These findings are particularly valuable when considering older patients, as they 
include not only grade 3 and higher events but also grade 1 and 2 events, which may be 
clinically relevant in elderly patients. A limitation of our analysis was that non-specific 
definitions of cardiac history precluded a detailed assessment of the impact of pre-existing 
cardiac conditions.
Due to the large number of patients included from rigorously conducted trials, and 
comprehensive adjudication of cardiac endpoints, this analysis provides an important 
benchmark of cardiac safety for proteasome inhibitors and MM drugs in general, and 
represents a reference point for future clinical studies. It provides criteria to define 
cardiotoxicity based upon individual MedDRA preferred terms and SMQs, plus data on 
multiple distinct, clinically relevant cardiac endpoints. Furthermore, the analysis addresses 
the challenges of mapping AEs consistently across studies utilising different AE definitions, 
and differences between NCI CTCAE (terms commonly encountered in oncology 
interventions, with a severity rating scale) and MedDRA (clinically validated, 
multidisciplinary list of >66 000 preferred terms, but without definitions or severity ratings). 
Although inherent discrepancies between NCI CTCAE and MedDRA may represent a 
limitation of our approach (Groarke et al, 2013), careful and diligent reclassification of 
relevant cardiac AEs across the 2 systems (and their various iterations), as well as the 
inclusive approach used, ensured a consistent and rigorous methodology.
To our knowledge, this is the first large analysis using patient-level data from multiple phase 
2 and 3 studies of bortezomib. This approach incorporated analysis of hazards and logistic 
regression for assessment of the influence of specific risk factors. It was assumed that each 
cardiac AE could occur independently, other than cardiac death, and, therefore, we did not 
conduct competing risks analyses; such analyses were not required due to the very low rates 
of cardiac deaths in the included studies. A recent pooled analysis employing only published 
study-level data and AEs reported in the respective publications provides supportive 
evidence that bortezomib does not significantly increase cardiotoxicity risk (Xiao et al, 
2014). Additionally, regarding the feasibility of bortezomib in the setting of cardiovascular 
risk, reports have indicated that bortezomib-based therapy may be administered successfully 
to amyloidosis patients, specifically patients with cardiac amyloid involvement (Charaf et al, 
2009; Dubrey et al, 2011; Freeman et al, 2012; Gatt et al, 2016; Mikhael et al, 2012; Reece 
et al, 2011; Tamaki et al, 2010), noting that all patients with existing heart disease or risk 
factors for heart disease should be closely monitored (http://www.velcade.com/files/pdfs/
velcade_prescribing_information.pdf). Indeed, in the phase 1 trial by Dubrey et al (2011), 
logitudinal echocardiographic study reported no cardiac responses to bortezomib therapy in 
patients with relapsed AL amyloidosis. However, it should be highlighted that in the studies 
in the present analysis, patients with New York Heart Association class II/III–IV CHF and/or 
known amyloidosis were excluded and, except in VISTA, median ages were generally 
relatively lower versus the overall patient population; thus, a standard MM patient 
population may include more patients at higher risk of cardiovascular complications. While 
our findings may be broadly applicable to the wider MM patient population, due to 
employing data from selected clinical trial populations with specific cardiac exclusion 
criteria (Table I), they are not necessarily generalisable to patients with a higher burden of 
cardiovascular disease or recent/ongoing cardiac comorbidities.
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The apparent overall higher incidence of cardiac events in VISTA compared with other 
studies may be due to patients being approximately 10 years older, based on median ages, or 
having a higher rate of prior cardiac history. Transplant-ineligible patients aged ≥65 years 
represent the majority of MM patients – approximately two-thirds – at initial diagnosis 
(Mateos & San Miguel, 2013), underlining the importance of understanding cardiac profiles 
of MM drugs. There were no differences between VMP and MP in VISTA, except for 
incidence of oedema, which does not appear to have a cardiac aetiology. This finding, 
combined with logistic regression results, suggests bortezomib can be used safely in this 
patient population. VISTA data challenge the common perception that RRMM patients may 
per se have higher risk of cardiac events in addition to the higher age of patients. However, 
these findings may have been a result of patients having a more complete medical history in 
VISTA versus other trials. Potential differences in AE reporting and eligibility criteria must 
be considered when assessing safety data across different studies.
We speculate on several possible reasons for the higher incidence of oedema with VMP 
versus MP in VISTA and in the pooled transplant analysis, and the trend towards higher 
incidences of hypertension. There may be some contribution directly via proteasome 
inhibition (http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf), 
including potentially a low-level cardiac effect, and there may be other, less serious types of 
oedema included. There may be an element of endothelial leak and fluid retention, 
associated with activity of proteasome inhibition on the endothelium and its anti-angiogenic 
effects (Belloni et al, 2010; Roccaro et al, 2006), and possibly potentiated by the synergy 
between proteasome inhibition and alkylating agents (Ma et al, 2003; Mitsiades et al, 2003) 
and the long exposure to prednisone (San Miguel et al, 2008).
All proteasome inhibitors have unique characteristics, with potentially distinct mechanistic 
differences, pharmacological characteristics and safety profiles (Moreau et al, 2012; Allegra 
et al, 2014; McBride & Ryan, 2013). Respective relative effects on the central/peripheral 
nervous system, gastrointestinal system, bone marrow and cardiovascular system may differ 
(Cavo et al, 2010; Harousseau et al, 2010; Richardson et al, 2003; Richardson et al, 2005; 
Rosinol et al, 2012; San Miguel et al, 2008; Sonneveld et al, 2012; Sonneveld et al, 2013; 
Moreau et al, 2011; Orlowski et al, 2007; Lonial et al, 2012; Siegel et al, 2013; Touzeau et 
al, 2013). Further studies are needed to better define these differences. No comparisons can 
be made with this analysis or conclusions drawn from available findings. Data on cardiac 
AEs in early-phase carfilzomib studies have been published, and the phase 3 ENDEAVOR 
(Carfilzomib and dexamethasone versus bortezomib and dexamethasone for RRMM 
patients) trial reported that 2 patients in each arm had significant left ventricular ejection 
fraction reductions during the study and that rates of grade ≥3 cardiac failure were 1·8% 
versus 4·8%, grade ≥3 pulmonary hypertension were <1% versus <1% and grade ≥3 IHD 
were 1·5% versus 1·7%, respectively (Dimopoulos et al, 2016). In the ASPIRE (Carfilzomib, 
lenalidomide, and dexamethasone versus lenalidomide and dexamethasone for the treatment 
of patients with relapsed multiple myeloma) phase 3 trial, rates of grade ≥3 cardiac failure 
were 3·8% versus 1·8%, and grade ≥3 hypertension rates were 4·3% versus 1·8% (Stewart et 
al, 2015). A pooled analysis of phase 2 studies in 526 RRMM patients (70% with baseline 
cardiac risk factors [use of ≥1 prior cardiovascular or anti-diabetic medication]), 53% of 
whom received the approved 20/27 mg/m2 dose, reported 7·2% cardiac failure (5·7% grade 
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≥3), 13·3% (2·3%) cardiac arrhythmia, 3·4% (1·3%) IHD, 42·2% (4·9%) dyspnoea and 
14·3% hypertension, with 1·5% cardiac-related deaths (Lonial et al, 2012; Siegel et al, 
2013). Other cardiac AE data have been reported from a phase 1/2 study of carfilzomib-MP 
(Touzeau et al, 2013), a compassionate-use analysis of carfilzomib in RRMM (Atrash et al, 
2015), and a phase 2 study of carfilzomib 56 mg/m2 with/without dexamethasone in RRMM 
(Lendvai et al, 2014). Phase 3 data on the oral proteasome inhibitor ixazomib in combination 
with lenalidomide and dexamethasone in RRMM have recently been published (Moreau et 
al, 2016); rates of heart failure with ixazomib + lenalidomide/dexamethasone were 4% (2% 
grade 3; <1% grade 4), arrythmia 16% (5% grade 3; <1% grade 4), hypertension 6% (3% 
grade 3) and myocardial infarction 1% (<1% grade 4). A recent case report also described an 
instance of acutely decompensated heart failure that was considered as being induced by 
ixazomib; the patient’s cardiac function did not improve within 6 months of ixazomib 
discontinuation, but no further episodes of systolic heart failure were observed (Jouni et al, 
2016). Data on cardiac AEs with the investigational proteasome inhibitors oprozomib and 
marizomib are limited. These findings provide support for the methodological approach 
taken in these analyses, which focus not just on CHF but other specific endpoints of cardiac 
aetiology that are relevant in MM treatment.
Non-clinical studies have suggested possible links between proteasome inhibition and the 
cardiovascular system, with studies demonstrating the importance of the ubiquitin-
proteasome system, including in heart remodelling (Li & Wang, 2011; Portbury et al, 2012; 
Su & Wang, 2010; Willis & Patterson, 2013). Furthermore, studies have identified multiple 
effects of proteasome inhibition on the cardiovascular system, with a differential impact of 
different proteasome inhibitors on cardiac proteasome subtypes (Kloss et al, 2010; Powell et 
al, 2012; Scruggs et al, 2011) in 1 study (Kloss et al, 2010). These data further highlight the 
importance of analysing the cardiovascular risk associated with proteasome inhibitors and 
other novel agents for MM treatment (Groarke et al, 2013).
In conclusion, these data from bortezomib studies provide a benchmark for evaluating 
cardiovascular risk associated with proteasome inhibition in MM; data from ongoing 
prospective and comparative studies are necessary to determine whether proteasome 
inhibitors have different cardiotoxicity profiles. A better understanding of the mechanism of 
proteasome inhibitor-induced cardiotoxicity, risk factors and potential biomarkers 
identifying at-risk patient populations will be critical. Furthermore, it will be important to 
improve reporting of baseline cardiac risk factors, cardiac AEs and detection of 
cardiotoxicity in the context of oncology clinical trials. The NCI CTCAE provide for 
standardised AE reporting in cancer trials, but the methodology differs compared with 
cardiovascular trials; thus, early, asymptomatic cardiac changes may not be identified using 
NCI CTCAE. To facilitate assessment of cardiac AEs, there may be a need for improved 
cardiac monitoring in future studies of proteasome inhibitors and other drugs to elucidate 
any differential cardiac effects of these agents, especially as combination approaches in MM 
with other novel agents are pursued (Lonial et al, 2011). More broadly, in the context of the 
abundance of novel agents either already approved or in development for the treatment of 
MM, it will be critical to gain an improved understanding of cardiac events associated with 
individual agents. Our analyses represent a broadly applicable, comprehensive, reproducible 
and consistent methodology for the standardised assessment of cardiac toxicity in MM.
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Time to first onset of CHF and dyspnoea in (A, B) VISTA (San Miguel et al, 2008), (C, D) 
the pooled transplant analysis and (E, F) APEX.
HR shown for time to first onset of CHF or dyspnoea. Circles represent individual censored 
observations.
APEX, Assessment of Proteasome Inhibition for Extending Remissions study;Btz, 
bortezomib; CHF, congestive heart failure; Dex, dexamethasone; HR, hazard ratio; MP, 
melphalan-prednisone; VISTA, VELCADE® as Initial Standard Therapy in Multiple 
Myeloma: Assessment with Melphalan and Prednisone study; VMP, bortezomib-melphalan-
prednisone.
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